Product Information
IBUPROFEN-FAMOTIDIN 800-26.6 MG is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.7138 per EA under NDC 31722031590. Its NADAC has been published 156 times since Oct 11, 2023.
FDA first approved this application on Mar 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
26.6; 800 mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722031590
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FAMOTIDINE; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA216814FDA Approved
3/15/2023
TE Code
AB
On Market Since
3/15/2023
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has been published 156 times since Oct 11, 2023, and over the history we have for it it has declined 77.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7138 per EA |
|---|---|
| All-time high | $3.1024 (Dec 13, 2023) |
| All-time low | $0.6418 (Feb 18, 2026) |
| 52-week high | $0.9449 |
| 52-week low | $0.6418 |
| Median price | $0.9826 |
| Average price | $1.3017 |
| Largest weekly change | -44.8% (Mar 20, 2024) |
| Weeks tracked | 156 |
| Tracking since | Oct 11, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen and famotidine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-2 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN-FAMOTIDIN 800-26.6 MG?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN-FAMOTIDIN 800-26.6 MG, manufactured by Camber Pharmaceuticals Inc., is $0.7138 per EA (NDC 31722031590), effective Sep 30, 2026.
How has the price of IBUPROFEN-FAMOTIDIN 800-26.6 MG changed over time?
Over the history we have for it, the NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has declined 77.0%. It has been tracked across 156 weekly CMS publications since Oct 11, 2023.
What are the highest and lowest recorded NADAC prices for IBUPROFEN-FAMOTIDIN 800-26.6 MG?
Since Oct 11, 2023, the NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has ranged from a low of $0.6418 (Feb 18, 2026) to a high of $3.1024 (Dec 13, 2023), with a median of $0.9826 per EA.
Are there cheaper alternatives to IBUPROFEN-FAMOTIDIN 800-26.6 MG?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IBUPROFEN-FAMOTIDIN 800-26.6 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures IBUPROFEN-FAMOTIDIN 800-26.6 MG?
IBUPROFEN-FAMOTIDIN 800-26.6 MG (NDC 31722031590) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.